niacinamide has been researched along with Necrosis in 62 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)." | 7.85 | Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017) |
| "Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the most frequent form of primary liver tumour." | 7.81 | The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. ( Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z, 2015) |
| "Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC)." | 7.81 | Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC, 2015) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 7.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| "To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC)." | 7.80 | Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. ( Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K, 2014) |
| "The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines." | 7.79 | Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013) |
| "To investigate the effects of sorafenib when combined with radiofrequency ablation treatment in liver tissue, the necrosis volume, tissue repair and hepatocellular growth signals were analyzed in rats." | 7.78 | Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. ( Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J, 2012) |
| "Twenty-five patients with inoperable hepatocellular carcinoma receiving oral sorafenib underwent magnetic resonance imaging at baseline and follow-up every 8 weeks (range, 2-19 weeks; mean, 7." | 7.77 | Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. ( Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D, 2011) |
| " We previously showed that the multikinase inhibitor sorafenib activated GSK-3β and that this activation attenuated the cytotoxic effects of the drug in various BRAF-mutant melanoma cell lines." | 7.77 | Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. ( Liu, Q; Mier, JW; Panka, DJ, 2011) |
| "As sorafenib induces early intralesional necrosis with profound changes in T1WI/T2WI MRI signal intensities and measurable necrotic tumor areas in most HCC patients, early MRI-based evaluation could pave the way for its rationale and cost-effective application." | 7.75 | Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. ( Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C, 2009) |
| "Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer." | 5.17 | Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. ( Agrawal, S; Choudhury, A; Denley, H; Eustace, A; Harris, AL; Hoskin, PJ; Irlam, JJ; Ord, JJ; Rojas, AM; Ryder, D; Taylor, J; West, CM, 2013) |
| "In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)." | 3.85 | Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017) |
| "To investigate feasibility, safety, and effect of transarterial chemoembolization using sorafenib on degree of tumor necrosis in a rabbit VX2 liver tumor model." | 3.83 | Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect. ( Kim, do Y; Kim, GM; Kim, MD; Kim, SH; Lee, do Y; Park, SI; Shin, M; Shin, W; Won, JY, 2016) |
| " Ex vivo treatment with 20 µM sorafenib induced apoptosis in around 80 % myeloma cells from six multiple myeloma patients." | 3.81 | Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. ( Anel, A; Azaceta, G; Galán-Malo, P; Jarauta, V; López-Royuela, N; Marzo, I; Naval, J; Palomera, L; Pardo, J; Ramírez-Labrada, A, 2015) |
| "Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the most frequent form of primary liver tumour." | 3.81 | The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. ( Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z, 2015) |
| "Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC)." | 3.81 | Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC, 2015) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 3.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| "To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC)." | 3.80 | Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. ( Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K, 2014) |
| "Ferroptosis is a recently identified form of regulated necrosis that can be experimentally induced in cancer cells with the chemical inducer erastin." | 3.80 | Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. ( Baert, M; Chauffert, B; Diouf, M; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Saidak, Z, 2014) |
| "The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines." | 3.79 | Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013) |
| "To investigate the effects of sorafenib when combined with radiofrequency ablation treatment in liver tissue, the necrosis volume, tissue repair and hepatocellular growth signals were analyzed in rats." | 3.78 | Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. ( Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J, 2012) |
| "Twenty-five patients with inoperable hepatocellular carcinoma receiving oral sorafenib underwent magnetic resonance imaging at baseline and follow-up every 8 weeks (range, 2-19 weeks; mean, 7." | 3.77 | Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. ( Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D, 2011) |
| " We previously showed that the multikinase inhibitor sorafenib activated GSK-3β and that this activation attenuated the cytotoxic effects of the drug in various BRAF-mutant melanoma cell lines." | 3.77 | Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. ( Liu, Q; Mier, JW; Panka, DJ, 2011) |
| "As sorafenib induces early intralesional necrosis with profound changes in T1WI/T2WI MRI signal intensities and measurable necrotic tumor areas in most HCC patients, early MRI-based evaluation could pave the way for its rationale and cost-effective application." | 3.75 | Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. ( Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C, 2009) |
| " administration of D-galactosamine, and it rather showed a decrease together with necrosis after carbon tetrachloride administration." | 3.68 | N1-methylnicotinamide level in the blood after nicotinamide loading as further evidence for malignant tumor burden. ( Fujimura, S; Kato, N; Miyazaki, M; Moriyama, Y; Nakagawa, K; Okui, K, 1991) |
| "Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy." | 3.01 | Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). ( Choudhury, A; Hoskin, PJ; Irlam, J; Lane, B; Mistry, H; Song, YP; Valentine, H; West, C; Yang, L, 2021) |
| "The osteosarcoma was only partially sensitive to the molecular-targeting drug sorafenib, which did not arrest its growth." | 1.46 | Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. ( Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M, 2017) |
| "Insufficient thermal ablation promotes residual tumor progression." | 1.43 | Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model. ( Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL, 2016) |
| "Relapsed/refractory Hodgkin's lymphoma (HL) is an unmet medical need requiring new therapeutic options." | 1.40 | BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. ( Anichini, A; Carbone, A; Carlo-Stella, C; Cleris, L; Locatelli, SL; Malorni, W; Pierdominici, M; Saba, E; Stirparo, GG; Tartari, S, 2014) |
| "Sorafenib was acutely administered to NASH rats with IR liver injury that were or were not chronically pretreated with the Rho-kinase-specific inhibitor fasudil." | 1.38 | Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. ( Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC, 2012) |
| "Spontaneous pyopneumothorax is a very rare occurrence, even in cancer treated patients." | 1.36 | Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. ( Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S, 2010) |
| "Necrosis was also induced by DEVD-fmk, but not by YVAD-cmk, indicating that only inhibitors of caspase-3 were able to cause necrosis." | 1.32 | Inhibition of caspase-mediated PARP-1 cleavage results in increased necrosis in isolated islets of Langerhans. ( Aikin, R; Maysinger, D; Paraskevas, S; Rosenberg, L, 2004) |
| " However, the dosage and time of treatment require clarification." | 1.31 | Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. ( Adams, JD; Chan, P; Chang, ML; Kem, S; Klaidman, LK; Sugawara, T; Yang, J, 2002) |
| " Furthermore, chronic administration of 0." | 1.27 | Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats. ( Denda, A; Emi, Y; Konishi, Y; Mikami, S; Nakae, D; Ohnishi, T; Takahashi, S; Yokose, Y, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (25.81) | 18.7374 |
| 1990's | 7 (11.29) | 18.2507 |
| 2000's | 8 (12.90) | 29.6817 |
| 2010's | 30 (48.39) | 24.3611 |
| 2020's | 1 (1.61) | 2.80 |
| Authors | Studies |
|---|---|
| Song, YP | 1 |
| Mistry, H | 1 |
| Irlam, J | 1 |
| Valentine, H | 1 |
| Yang, L | 1 |
| Lane, B | 1 |
| West, C | 1 |
| Choudhury, A | 2 |
| Hoskin, PJ | 2 |
| Chen, D | 1 |
| Eyupoglu, IY | 1 |
| Savaskan, N | 1 |
| Martens, S | 1 |
| Jeong, M | 1 |
| Tonnus, W | 1 |
| Feldmann, F | 1 |
| Hofmans, S | 1 |
| Goossens, V | 1 |
| Takahashi, N | 1 |
| Bräsen, JH | 1 |
| Lee, EW | 1 |
| Van der Veken, P | 1 |
| Joossens, J | 1 |
| Augustyns, K | 1 |
| Fulda, S | 1 |
| Linkermann, A | 1 |
| Song, J | 1 |
| Vandenabeele, P | 1 |
| Paech, F | 1 |
| Mingard, C | 1 |
| Grünig, D | 1 |
| Abegg, VF | 1 |
| Bouitbir, J | 1 |
| Krähenbühl, S | 1 |
| Pajuelo, D | 1 |
| Gonzalez-Juarbe, N | 1 |
| Tak, U | 1 |
| Sun, J | 1 |
| Orihuela, CJ | 1 |
| Niederweis, M | 1 |
| Carlo-Stella, C | 3 |
| Locatelli, SL | 3 |
| Giacomini, A | 2 |
| Cleris, L | 3 |
| Saba, E | 2 |
| Righi, M | 1 |
| Guidetti, A | 2 |
| Gianni, AM | 2 |
| Eustace, A | 1 |
| Irlam, JJ | 1 |
| Taylor, J | 1 |
| Denley, H | 1 |
| Agrawal, S | 1 |
| Ryder, D | 1 |
| Ord, JJ | 1 |
| Harris, AL | 1 |
| Rojas, AM | 1 |
| West, CM | 1 |
| Jakubowicz-Gil, J | 1 |
| Langner, E | 1 |
| Bądziul, D | 1 |
| Wertel, I | 1 |
| Rzeski, W | 1 |
| Stirparo, GG | 1 |
| Tartari, S | 1 |
| Pierdominici, M | 1 |
| Malorni, W | 1 |
| Carbone, A | 1 |
| Anichini, A | 2 |
| Fukuda, H | 1 |
| Numata, K | 1 |
| Moriya, S | 1 |
| Shimoyama, Y | 1 |
| Ishii, T | 2 |
| Nozaki, A | 1 |
| Kondo, M | 1 |
| Morimoto, M | 1 |
| Maeda, S | 1 |
| Sakamaki, K | 1 |
| Morita, S | 1 |
| Tanaka, K | 3 |
| Ramírez-Labrada, A | 1 |
| López-Royuela, N | 1 |
| Jarauta, V | 1 |
| Galán-Malo, P | 1 |
| Azaceta, G | 1 |
| Palomera, L | 1 |
| Pardo, J | 1 |
| Anel, A | 1 |
| Marzo, I | 1 |
| Naval, J | 1 |
| Lachaier, E | 2 |
| Louandre, C | 3 |
| Godin, C | 3 |
| Saidak, Z | 3 |
| Baert, M | 1 |
| Diouf, M | 2 |
| Chauffert, B | 3 |
| Galmiche, A | 3 |
| Marcq, I | 1 |
| Bouhlal, H | 1 |
| François, C | 1 |
| Chatelain, D | 1 |
| Debuysscher, V | 1 |
| Barbare, JC | 2 |
| Suzuki, E | 1 |
| Ooka, Y | 1 |
| Chiba, T | 1 |
| Kobayashi, K | 1 |
| Kanogawa, N | 1 |
| Motoyama, T | 1 |
| Saito, T | 1 |
| Ogasawara, S | 1 |
| Tawada, A | 1 |
| Yokosuka, O | 1 |
| Bodeau, S | 1 |
| Conte, MA | 1 |
| Barget, N | 1 |
| Trinchet, JC | 1 |
| Ganne, N | 1 |
| Araki, H | 1 |
| Tsuzuki, T | 1 |
| Kimura, T | 1 |
| Yamada, S | 1 |
| Sassa, N | 1 |
| Yoshino, Y | 1 |
| Hattori, R | 1 |
| Gotoh, M | 1 |
| Kharaziha, P | 1 |
| Chioureas, D | 1 |
| Baltatzis, G | 1 |
| Fonseca, P | 1 |
| Rodriguez, P | 1 |
| Gogvadze, V | 1 |
| Lennartsson, L | 1 |
| Björklund, AC | 1 |
| Zhivotovsky, B | 1 |
| Grandér, D | 1 |
| Egevad, L | 1 |
| Nilsson, S | 1 |
| Panaretakis, T | 1 |
| Kim, GM | 1 |
| Kim, MD | 1 |
| Kim, do Y | 1 |
| Kim, SH | 1 |
| Won, JY | 1 |
| Park, SI | 1 |
| Lee, do Y | 1 |
| Shin, W | 1 |
| Shin, M | 1 |
| Kong, WT | 1 |
| Cai, H | 1 |
| Tang, Y | 1 |
| Zhang, XL | 1 |
| Wang, WP | 1 |
| Frederick, DW | 1 |
| Loro, E | 1 |
| Liu, L | 1 |
| Davila, A | 1 |
| Chellappa, K | 1 |
| Silverman, IM | 1 |
| Quinn, WJ | 1 |
| Gosai, SJ | 1 |
| Tichy, ED | 1 |
| Davis, JG | 1 |
| Mourkioti, F | 1 |
| Gregory, BD | 1 |
| Dellinger, RW | 1 |
| Redpath, P | 1 |
| Migaud, ME | 1 |
| Nakamaru-Ogiso, E | 1 |
| Rabinowitz, JD | 1 |
| Khurana, TS | 1 |
| Baur, JA | 1 |
| Murakami, T | 1 |
| Igarashi, K | 1 |
| Kawaguchi, K | 1 |
| Kiyuna, T | 1 |
| Zhang, Y | 1 |
| Zhao, M | 1 |
| Hiroshima, Y | 1 |
| Nelson, SD | 1 |
| Dry, SM | 1 |
| Li, Y | 1 |
| Yanagawa, J | 1 |
| Russell, T | 1 |
| Federman, N | 1 |
| Singh, A | 1 |
| Elliott, I | 1 |
| Matsuyama, R | 1 |
| Chishima, T | 1 |
| Endo, I | 1 |
| Eilber, FC | 1 |
| Hoffman, RM | 1 |
| Tang, Z | 1 |
| Kang, M | 1 |
| Zhang, B | 1 |
| Chen, J | 1 |
| Fang, H | 1 |
| Ye, Q | 1 |
| Jiang, B | 1 |
| Wu, Y | 1 |
| Korkmaz, S | 1 |
| Maupoil, V | 1 |
| Sobry, C | 2 |
| Brunet, C | 1 |
| Chevalier, S | 2 |
| Freslon, JL | 1 |
| Horger, M | 2 |
| Lauer, UM | 2 |
| Schraml, C | 1 |
| Berg, CP | 1 |
| Koppenhöfer, U | 1 |
| Claussen, CD | 2 |
| Gregor, M | 2 |
| Bitzer, M | 2 |
| Ladoire, S | 1 |
| Beynat, C | 1 |
| Diaz, P | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Ghiringhelli, F | 1 |
| Spira, D | 1 |
| Fenchel, M | 1 |
| Mertens, JC | 1 |
| Martin, IV | 1 |
| Schmitt, J | 1 |
| Frei, P | 1 |
| Bruners, P | 1 |
| Herweg, C | 1 |
| Mahnken, AH | 1 |
| Müllhaupt, B | 1 |
| Geier, A | 1 |
| Liu, Q | 1 |
| Mier, JW | 1 |
| Panka, DJ | 1 |
| Petrov, VI | 1 |
| Ponomarev, ÉA | 1 |
| Maskin, SS | 1 |
| Strepetov, NN | 1 |
| Fabries, P | 1 |
| Pauleau, G | 1 |
| Brardjanian, S | 1 |
| Artéaga, C | 1 |
| Guisset, M | 1 |
| Coton, T | 1 |
| Tong, DL | 1 |
| Zhang, DX | 1 |
| Xiang, F | 1 |
| Teng, M | 1 |
| Jiang, XP | 1 |
| Hou, JM | 1 |
| Zhang, Q | 1 |
| Huang, YS | 1 |
| Yang, YY | 1 |
| Huang, YT | 1 |
| Lee, TY | 1 |
| Chan, CC | 1 |
| Yeh, YC | 1 |
| Lee, KC | 1 |
| Lin, HC | 1 |
| Mortarini, R | 1 |
| Yang, J | 1 |
| Klaidman, LK | 1 |
| Chang, ML | 1 |
| Kem, S | 1 |
| Sugawara, T | 1 |
| Chan, P | 1 |
| Adams, JD | 1 |
| Piro, S | 1 |
| Anello, M | 1 |
| Di Pietro, C | 1 |
| Lizzio, MN | 1 |
| Patanè, G | 1 |
| Rabuazzo, AM | 1 |
| Vigneri, R | 1 |
| Purrello, M | 1 |
| Purrello, F | 1 |
| Tronov, VA | 1 |
| Konstantinov, EM | 1 |
| Petrakou, E | 1 |
| Tsilimigaki, S | 1 |
| Piperakis, SM | 1 |
| Aikin, R | 1 |
| Rosenberg, L | 1 |
| Paraskevas, S | 1 |
| Maysinger, D | 1 |
| Hanton, G | 1 |
| Daguès, N | 1 |
| Provost, JP | 1 |
| Le Net, JL | 1 |
| Comby, P | 1 |
| Takahashi, S | 1 |
| Nakae, D | 1 |
| Yokose, Y | 1 |
| Emi, Y | 1 |
| Denda, A | 1 |
| Mikami, S | 1 |
| Ohnishi, T | 1 |
| Konishi, Y | 1 |
| Elliott, WC | 1 |
| Houghton, DC | 1 |
| Gilbert, DN | 1 |
| Baines-Hunter, J | 1 |
| Bennett, WM | 1 |
| Watson, AJ | 1 |
| Askew, JN | 1 |
| Benson, RS | 1 |
| Thomas, CD | 1 |
| Prade, M | 1 |
| Guichard, M | 1 |
| de Ferreyra, EC | 1 |
| Bernacchi, AS | 1 |
| San Martín, MF | 1 |
| Castro, GD | 1 |
| Castro, JA | 1 |
| Saldeen, J | 1 |
| Welsh, N | 1 |
| Hoorens, A | 1 |
| Pipeleers, D | 1 |
| Chatterjee, PK | 1 |
| Cuzzocrea, S | 1 |
| Thiemermann, C | 1 |
| Harel, A | 1 |
| Bloch, O | 1 |
| Vardi, P | 1 |
| Bloch, K | 1 |
| Schoental, R | 2 |
| Horita, N | 1 |
| Oyanagi, S | 1 |
| Izumiyama, Y | 1 |
| Szalay, J | 1 |
| Böti, Z | 1 |
| Temesvári, P | 1 |
| Bara, D | 1 |
| Nakagawa, K | 1 |
| Miyazaki, M | 1 |
| Okui, K | 1 |
| Kato, N | 1 |
| Moriyama, Y | 1 |
| Fujimura, S | 1 |
| Politis, MJ | 1 |
| Render, JA | 1 |
| Carlton, WW | 1 |
| Hinsman, EJ | 1 |
| Turek, JJ | 1 |
| Chen, G | 1 |
| Pan, QC | 1 |
| Lazarus, SS | 1 |
| Shapiro, SH | 1 |
| Severin, SE | 1 |
| Hill, K | 1 |
| Neidhardt, M | 1 |
| Hirsch, GH | 1 |
| Herken, H | 1 |
| Keller, K | 1 |
| Kolbe, H | 1 |
| Lange, K | 1 |
| Schneider, H | 2 |
| Cervos-Navarro, J | 1 |
| Schweichel, JU | 1 |
| Merker, HJ | 1 |
2 trials available for niacinamide and Necrosis
| Article | Year |
|---|---|
Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbon Dioxide; Confidence Intervals; Disease-Fre | 2021 |
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carbonic Anhydrase IV; Cell Hypoxia; Female; Glucose Transp | 2013 |
60 other studies available for niacinamide and Necrosis
| Article | Year |
|---|---|
Ferroptosis and Cell Death Analysis by Flow Cytometry.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dactinomycin; Flow Cytom | 2017 |
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.
Topics: Animals; Apoptosis; Cell Death; Disease Models, Animal; Humans; Inflammation; Mice; Necrosis; Niacin | 2017 |
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; | 2018 |
NAD
Topics: Animals; Apoptosis; Bacterial Toxins; Biocatalysis; Cytoprotection; Humans; Jurkat Cells; Macrophage | 2018 |
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell | 2013 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combinatio | 2014 |
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carbamates; Cell Line, Tum | 2014 |
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Co | 2014 |
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibito | 2015 |
Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Humans; L-Lactate Dehydrogenase | 2014 |
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Prolif | 2015 |
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; In | 2015 |
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Kerat | 2015 |
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; D | 2015 |
Sorafenib-induced defective autophagy promotes cell death by necroptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western | 2015 |
Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepato | 2016 |
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magn | 2016 |
Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle.
Topics: Administration, Oral; Aging; Animals; Biological Availability; Energy Metabolism; Glucose; Homeostas | 2016 |
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neo | 2017 |
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, An | 2017 |
An increased regional blood flow precedes mesenteric inflammation in rats treated by a phosphodiesterase 4 inhibitor.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Analysis of Variance; Animals; A | 2009 |
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Li | 2009 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Rena | 2010 |
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular | 2011 |
Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals.
Topics: Alanine Transaminase; Animals; Benzenesulfonates; Catheter Ablation; Cell Proliferation; Epidermal G | 2012 |
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; | 2011 |
[Pharmacological neuroprotection against brain damage in ischemiai/reperfusion experiment].
Topics: Animals; Brain; Drug Combinations; Drug Evaluation, Preclinical; Eosine Yellowish-(YS); Flavin Monon | 2011 |
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, H | 2013 |
Nicotinamide pretreatment protects cardiomyocytes against hypoxia-induced cell death by improving mitochondrial stress.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Apoptosis; Cell Hypoxia; Cells, Cultured; L-Lacta | 2012 |
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; He | 2012 |
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; C | 2013 |
Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model.
Topics: Animals; Apoptosis; Brain; Dose-Response Relationship, Drug; Male; Necrosis; Niacinamide; Rats; Rats | 2002 |
Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress.
Topics: Animals; Annexin A5; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase | 2002 |
Nicotinamide "protects" resting lymphocytes exposed to hydrogen peroxide from necrosis but not from apoptosis.
Topics: Apoptosis; Cell Survival; Comet Assay; DNA Damage; DNA Fragmentation; DNA Repair; Electrophoresis, A | 2002 |
Inhibition of caspase-mediated PARP-1 cleavage results in increased necrosis in isolated islets of Langerhans.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase Inhibitors; Caspases; Cell Death; Cells | 2004 |
Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog.
Topics: Acute-Phase Reaction; Administration, Oral; Animals; Azepines; Blood Vessels; C-Reactive Protein; Do | 2008 |
Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats.
Topics: Animals; Benzamides; Diethylnitrosamine; DNA Repair; gamma-Glutamyltransferase; Liver; Liver Neoplas | 1984 |
Gentamicin nephrotoxicity. I. Degree and permanence of acquired insensitivity.
Topics: Acute Kidney Injury; Animals; Gentamicins; Inulin; Kidney; Kidney Cortex; Male; Necrosis; Niacinamid | 1982 |
Poly(adenosine diphosphate ribose) polymerase inhibition prevents necrosis induced by H2O2 but not apoptosis.
Topics: Aminobenzoates; Apoptosis; Benzamides; Cell Count; Cell Line; DNA Repair; Humans; Hydrogen Peroxide; | 1995 |
Tumour oxygenation, radiosensitivity, and necrosis before and/or after nicotinamide, carbogen and perflubron emulsion administration.
Topics: Animals; Carbon Dioxide; Cell Survival; Fluorocarbons; Humans; Hydrocarbons, Brominated; Hypoxia; Mi | 1995 |
Nicotinamide late protective effects against carbon tetrachloride-induced liver necrosis.
Topics: Animals; Carbon Tetrachloride; Lipid Peroxidation; Liver; Male; Necrosis; Niacinamide; Rats; Rats, S | 1994 |
Nicotinamide-induced apoptosis in insulin producing cells is associated with cleavage of poly(ADP-ribose) polymerase.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Benzamides; Cell Line; Cysteine Proteinase Inhi | 1998 |
Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Cytokines; Humans; Hydrogen Peroxide; Interferon | 1999 |
Inhibitors of poly (ADP-ribose) synthetase protect rat proximal tubular cells against oxidant stress.
Topics: Animals; Benzamides; Catalase; Cells, Cultured; Deferoxamine; DNA Damage; Enzyme Activation; Enzyme | 1999 |
Sensitivity of HaCat keratinocytes to diabetogenic toxins.
Topics: Alloxan; Analysis of Variance; Apoptosis; Benzamides; Cell Line; Cell Survival; Enzyme Inhibitors; G | 2002 |
Proceedings: Is alkylation of nicotinamide the cause of liver necrosis that follows large doses of hepatocarcinogens?
Topics: Carcinogens; Chemical and Drug Induced Liver Injury; Liver; Necrosis; Niacinamide | 1975 |
Ultrastructure of 6-aminonicotinamide (6-an)--induced lesions in the central nervous system of rats.
Topics: 6-Aminonicotinamide; Animals; Anterior Horn Cells; Axons; Male; Microscopy, Electron; Necrosis; Neur | 1978 |
Alterations of the nucleus ruber in 3-acetylpyridine intoxication. A light and electron microscopic study.
Topics: Animals; Antimetabolites; Female; Male; Microscopy, Electron; Mitochondria; Necrosis; Niacinamide; O | 1979 |
Biochemical basis of liver necrosis caused by pyrrolizidine alkaloids and certain other hepatotoxins.
Topics: Alkylation; Animals; Chemical and Drug Induced Liver Injury; NAD; Necrosis; Niacinamide; Pyridones; | 1975 |
N1-methylnicotinamide level in the blood after nicotinamide loading as further evidence for malignant tumor burden.
Topics: Animals; Carbon Tetrachloride Poisoning; Cells, Cultured; DNA Replication; Galactosamine; Inflammati | 1991 |
6-Aminonicotinamide selectively causes necrosis in reactive astroglia cells in vivo. Preliminary morphological observations.
Topics: 6-Aminonicotinamide; Animals; Astrocytes; Cell Nucleus; Male; Necrosis; Nerve Degeneration; Niacinam | 1989 |
Pathology of 6-aminonicotinamide toxicosis in the rabbit.
Topics: 6-Aminonicotinamide; Animals; Female; Injections, Intraperitoneal; Male; Microscopy, Electron; Necro | 1985 |
Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Ehrlich Tumor; Cispl | 1988 |
Influence of nicotinamide and pyridine nucleotides on streptozotocin and alloxan-induced pancreatic B cell cytotoxicity.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Islets of Langerhans; Male; Mice; NAD; | 1973 |
[Basic directions in the study of the biochemistry of the myocardium].
Topics: Adaptation, Physiological; Animals; Camphor; Cardiac Glycosides; Cardiomegaly; Cardiovascular Diseas | 1967 |
[Familial, infantile-septic chronic granulomatous disease: pathology and pathogenesis].
Topics: Child, Preschool; Granuloma; Histiocytes; Humans; Leukocytes; Male; Necrosis; Niacinamide; Oxidoredu | 1970 |
Stimulation of renal organic base transport by uranyl nitrate.
Topics: Aminohippuric Acids; Animals; Biological Transport; Body Weight; Carbon Isotopes; Kidney; Kinetics; | 1972 |
[Experimental myelopathy--biochemical basis of its cellular pathogenesis (author's transl)].
Topics: Animals; Brain Chemistry; Disease Models, Animal; Endoplasmic Reticulum; Gluconates; Glycoside Hydro | 1973 |
Acute gliopathy in spinal cord and brain stem induced by 6-aminonicotinamide.
Topics: Animals; Brain Stem; Cats; Cell Nucleus; Cerebellum; Cranial Nerves; Cytoplasm; Endoplasmic Reticulu | 1974 |
The morphology of various types of cell death in prenatal tissues.
Topics: Abnormalities, Drug-Induced; Animals; Cell Survival; Cyclophosphamide; Dactinomycin; Embryo, Mammali | 1973 |